MMP13-responsive hydrogel microspheres for osteoarthritis treatment by precise delivery of celecoxib DOI Creative Commons

Honglin Xiang,

Chuan Zhang, Yongfu Xiong

et al.

Materials & Design, Journal Year: 2024, Volume and Issue: 241, P. 112966 - 112966

Published: April 21, 2024

Osteoarthritis (OA) is characterized by cartilage degradation, inflammatory responses, and osteophyte formation. Matrix metalloproteinase 13 (MMP13) a hallmark of OA development, increased MMP13 expression closely associated with extracellular matrix degradation. varies significantly at different stages progression. While cyclooxygenase 2 (COX-2) inhibitors are commonly used to treat OA, their long-term systemic administration increases the risks adverse effects. Therefore, aim achieving localized responsive delivery COX-2 inhibitor celecoxib, current study investigated an innovative MMP13-responsive micro-nano hydrogel microsphere system. Celecoxib-loaded cationic liposomes non-covalently attached within microsphere, enabling controlled drug release for treatment. In environment elevated expression, system degraded via action substrate peptide (MMP13sp), facilitating accelerated drug-loaded improve microenvironment rapidly. Compared phosphate-buffered saline solution hyaluronidase (HAase), prepared hyaluronic acid methacrylate microspheres HAMA/MMP13sp/Lipo@celecoxib exhibited rapid degradation in containing physiological concentration MMP13/HAase, demonstrating specific enzyme responsiveness precise anti-inflammatory release. The achieves intelligent controllable effectively decelerating disease progression promoting articular repair.

Language: Английский

Recent advances on stimuli-responsive biopolymer-based nanocomposites for drug delivery DOI

Renhua Xiao,

Guangying Zhou,

Yuming Wen

et al.

Composites Part B Engineering, Journal Year: 2023, Volume and Issue: 266, P. 111018 - 111018

Published: Sept. 21, 2023

Language: Английский

Citations

30
Stimuli‐Responsive Nanocarriers for Transcytosis‐Based Cancer Drug Delivery DOI Creative Commons

Zhehao Wang,

Yuji Sun,

Youqing Shen

et al.

Advanced NanoBiomed Research, Journal Year: 2024, Volume and Issue: 4(3)

Published: Jan. 8, 2024

Significant challenges persist in enhancing the delivery efficiency of tumor nanomedicines, predominantly due to difficulty successfully surpassing pathophysiological barriers. Enhancing penetration nanomedicines such conditions represents a pivotal goal advancing anticancer nanotherapeutics. Transcytosis emerges as promising solution this context, addressing limitations passive drug delivery. By harnessing diverse stimuli induce transcytosis, nanocarriers can achieve precise and deep penetration, resulting high therapeutic efficacy reduced systemic exposure compound. This review briefly examines various stimuli‐responsive nanosystems offers an overview outlook on development for transcytosis‐based cancer delivery, aiming provide informative insights design capable tissue enhanced efficacy.

Language: Английский

Citations

13
Stimulus-Responsive Drug Delivery Nanoplatforms for Inflammatory Bowel Disease Therapy DOI
Long Jiang, Xiaoya Liang,

Zuojin Ao

et al.

Acta Biomaterialia, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

12
Biomaterials for inflammatory bowel disease: treatment, diagnosis and organoids DOI
Jia Wang, Yuying Shi,

Bei Mao

et al.

Applied Materials Today, Journal Year: 2024, Volume and Issue: 36, P. 102078 - 102078

Published: Jan. 20, 2024

Language: Английский

Citations

9
MMP13-responsive hydrogel microspheres for osteoarthritis treatment by precise delivery of celecoxib DOI Creative Commons

Honglin Xiang,

Chuan Zhang, Yongfu Xiong

et al.

Materials & Design, Journal Year: 2024, Volume and Issue: 241, P. 112966 - 112966

Published: April 21, 2024

Osteoarthritis (OA) is characterized by cartilage degradation, inflammatory responses, and osteophyte formation. Matrix metalloproteinase 13 (MMP13) a hallmark of OA development, increased MMP13 expression closely associated with extracellular matrix degradation. varies significantly at different stages progression. While cyclooxygenase 2 (COX-2) inhibitors are commonly used to treat OA, their long-term systemic administration increases the risks adverse effects. Therefore, aim achieving localized responsive delivery COX-2 inhibitor celecoxib, current study investigated an innovative MMP13-responsive micro-nano hydrogel microsphere system. Celecoxib-loaded cationic liposomes non-covalently attached within microsphere, enabling controlled drug release for treatment. In environment elevated expression, system degraded via action substrate peptide (MMP13sp), facilitating accelerated drug-loaded improve microenvironment rapidly. Compared phosphate-buffered saline solution hyaluronidase (HAase), prepared hyaluronic acid methacrylate microspheres HAMA/MMP13sp/Lipo@celecoxib exhibited rapid degradation in containing physiological concentration MMP13/HAase, demonstrating specific enzyme responsiveness precise anti-inflammatory release. The achieves intelligent controllable effectively decelerating disease progression promoting articular repair.

Language: Английский

Citations

9